Rabinowitz Matthew sold $299K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 748 shares of Natera, Inc. (NTRA) at an average of $400.02 ($388.20–$400.29, $0.30M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Nov 5, 2026, 2:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

Provides fresh, primary‑source data on insider activity for Natera.

02

Market read

Small insider sale; limited trading relevance.

03

What to watch

The insider retains over 2 million shares, indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold $299K of NTRA shares via a 10b5‑1 plan on 2026‑11‑02.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A $299K sale by a top executive signals potential concerns, but the amount is modest relative to total holdings.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited relevance to global markets.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Natera, Inc.

    US‑listed biotech firm (NASDAQ:NTRA).

  • Matthew Rabinowitz

    Executive Chairman of Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.